Imlifidase
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: HMED-IdeS, idefirix, IdeS
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Imlifidase is a drug catalogued in DrugCentral. It was first approved by the EMA in 2020. DrugCentral lists 1 molecular target, including IGHG1|IGHG2|IGHG3|IGHG4. Recorded indications include Renal transplant rejection and Transplant of kidney.
- Molecular targets: IGHG1|IGHG2|IGHG3|IGHG4 (1 listed in DrugCentral).
- Indications: Renal transplant rejection and Transplant of kidney.
- ATC code: L04AA41 (Selective immunosuppressants).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Renal transplant rejection
- Transplant of kidney
Contraindications (1)
- Thrombotic thrombocytopenic purpura
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Immunoglobulin gamma (IgG), heavy chain | IGHG1|IGHG2|IGHG3|IGHG4 | inhibitor | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2020-08-26 | EMA | — | Hansa Biopharma AB | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AA41 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1947415-68-0 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Imlifidase used for?
DrugCentral lists the following indications for Imlifidase: Renal transplant rejection and Transplant of kidney.
How does Imlifidase work?
Its molecular targets in DrugCentral include IGHG1|IGHG2|IGHG3|IGHG4 (inhibitor).
When was Imlifidase first approved?
Imlifidase was first approved by the EMA in 2020.
Browse: all drugs starting with I · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5418 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4297981 — compound record and bioactivity
- DrugBank DB15258 — drug record
- FDA UNII UVJ7NL8S2P — substance identity
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.